Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital

Hepatitis Monthly

Volumn 12, Issue 9, 2012, Pages

  Akbar, Hisham O ^a   Al Ghamdi, Ahmad ^a   Qattan, Faten ^a   Fallatah, Hind I ^a   Rumani, Maha Al ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Carcinoma; Chronic; Genotyping Techniques; Hepatitis C; Hepatocellular Ribavirin; Liver Cirrhosis; Saudi Arabia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PEGINTERFERON; PROTEIN; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SAUDI ARABIA; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA; THROMBOCYTE COUNT; THYROTOXICOSIS; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84867518198     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6178     Document Type: Article

References (41)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
2. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7(1):261-87.
3. Jadoul M, Barril G. Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission. Contrib Nephrol. 2012;176:35-41.
4. Akbar HO. Hepatitis C virus infection in Saudi Arabia. Saudi J Gastroenterol. 2004;10(3):127-31.
5. Al-Faleh FZ. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. Ann Saudi Med. 2003;23(6):367-71.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
8. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49(4):625-33.
9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-73.
10. Osoba AO, Ibrahim M, Abdelaal MA, Al-Mowallad A, Al Shareef B, Hussein BA. Hepatitis C virus genotyping by polymerase chain reaction and DNA enzyme immunoassay among Saudi patients in the Western Province, Saudi Arabia. Ann Saudi Med. 2000;20(5-6):394-7.
11. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:8-13.
12. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2010;7(9):485-94.
13. Daruich J. Chronic hepatitis C treatment in naive patients. Ann Hepatol. 2010;9 (Suppl):65-71.
14. Prati D, Gasbarrini A, Mazzotta F, al. e. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42(2):81-91.
15. de Galocsy C, Kaufman L, Tomasovic S, Delwaide J, Nevens F. Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1. Acta Gastroenterol Belg. 2010;73(2):229-34.
16. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135(2):451-8.
17. Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antivir Ther. 2009;14(2):143-54.
18. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52(4):1201-7.
19. Jacobson IM, Brown RS, Jr., Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46(4):971-81.
20. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
21. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344-55.
22. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.
23. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20.
24. Seeff LB. Strategies for assessing the long-term consequences of Hepatitis C virus infection. Minerva Gastroenterol Dietol. 2000;46(4):207-16.
25. Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med. 2007;27(3):191-4.
26. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J. 2003;24 (Suppl 2):S87-91.
27. al-Faleh FZ, Huraib S, Sbeih F, al-Karawi M, al-Rashed R, al-Mofleh IA, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat. 1995;2(6):293-6.
28. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182-8 e1.
29. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.
30. Shobokshi O, YASSIN ALS, Zaharna J, Mohammad A. The prevalence of hepatitis C virus in patients with established primary hepatocellular carcinoma in the western region of Saudi Arabia. Saudi Med J. 1996;17(5):570-5.
31. Merkinaite S, Lazarus JV, Gore C. Addressing HCV infection in Europe: reported, estimated and undiagnosed cases. Cent Eur J Public Health. 2008;16(3):106-10.
32. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des. 2008;14(17):1678-85.
33. Akbar HO, Fallatah HI. Serum ALT Levels in a Cohort of Healthy Blood Donors and Volunteers from Saudi Arabia: The Influence of Sex and Body Mass Index. Gastroentol Hepatol. 2010;1:13-9.
34. Huraib SO. Hepatitis C in dialysis patients. Saudi J Kidney Dis Transpl. 1995;6(2):197-205.
35. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4(1):207-20.
36. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
37. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010;9 (Suppl):119-22.
38. Dahlan Y, Ather HM, Al-ahmadi M, Batwa F, Al-hamoudi W. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. World J Gastroenterol. 2009;15(35):4429-33.
39. Ayyub MA, El-Moursy SA, Khazindar AM, Abbas FA. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease. Saudi Med J. 2009;30(5):712-6.
40. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336-45.
41. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010;15(5):687-95.